Full Text View
Tabular View
No Study Results Posted
Related Studies
Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients
This study has been completed.
Study NCT00034255   Information provided by GMP Endotherapeutics
First Received: April 24, 2002   Last Updated: June 23, 2005   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Additional conditions recognized in this trial
Diabetes Mellitus
More general conditions related to this trial
Autoimmune Diseases
Endocrine System Diseases
Glucose Metabolism Disorders
Immune System Diseases
Metabolic Diseases
Interventions listed in this trial
INGAP Peptide
Sponsors listed in this trial
GMP Endotherapeutics


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services